The Sybil prophecy: Searching for predictors of response to bevacizumab in glioblastoma

Neuro Oncol. 2024 Aug 5;26(8):1538-1539. doi: 10.1093/neuonc/noae088.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Angiogenesis Inhibitors / therapeutic use
  • Antineoplastic Agents, Immunological / therapeutic use
  • Bevacizumab* / therapeutic use
  • Brain Neoplasms* / drug therapy
  • Glioblastoma* / drug therapy
  • Glioblastoma* / pathology
  • Humans
  • Prognosis

Substances

  • Bevacizumab
  • Antineoplastic Agents, Immunological
  • Angiogenesis Inhibitors

Grants and funding